Evidence map›Paper›PMID 37480158›Full record

ArticlePediatric blood & cancer2023

Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation.

Carrie L Kitko, Catherine M Bollard, Mitchell S Cairo, Joseph Chewning, Terry J Fry, Michael A Pulsipher, Shalini Shenoy, Donna A Wall, John E Levine

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 2 countries.

Carrie L KitkoPediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0001-9216-2901
Catherine M BollardCenter for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.
Mitchell S CairoDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, Maria Fareri Children's Hospital, Westchester Medical Center, New York Medical College, Valhalla, New York, USA.ORCID 0000-0002-2075-434X
Joseph ChewningDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Terry J FryDepartment of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Michael A PulsipherDivision of Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine, Salt Lake City, Utah, USA.
Shalini ShenoyDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Washington University, St Louis, Missouri, USA.
Donna A WallDivision of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada.
John E LevineTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-5611-7828
Children's Hospital Colorado · USGeorge Washington University Hospital · USHospital for Sick Children · CAIcahn School of Medicine at Mount Sinai · USIntermountain Healthcare · USUniversity of Alabama at Birmingham · USVanderbilt University Medical Center · USWashington University in St. Louis · USWestchester Medical Center · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NIH HHS U10CA098413)NIH HHS U10CA098543NIH HHS U10CA180899
6 · The paper itself

Abstract

Since the publication of the last Cellular Therapy and Stem Cell Transplant blueprint in 2013, Children's Oncology Group cellular therapy-based trials advanced the field and created new standards of care across a wide spectrum of pediatric cancer diagnoses. Key findings include that tandem autologous transplant improved survival for patients with neuroblastoma and atypical teratoid/rhabdoid brain tumors, one umbilical cord blood (UCB) donor was safer than two UCB donors, killer immunoglobulin receptor (KIR) mismatched donors did not improve survival for pediatric acute myeloid leukemia when in vivo T-cell depletion is used, and the depth of remission as measured by next-generation sequencing-based minimal residual disease assessment pretransplant was the best predictor of relapse for acute lymphoblastic leukemia. Plans for the next decade include optimizing donor selection for transplants for acute leukemia/myelodysplastic syndrome, using novel engineered cellular therapies to target a wide array of malignancies, and developing better treatments for cellular therapy toxicities such as viral infections and graft-vs-host disease.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesChildHumansUnrelated DonorsALLAMLBMTCNS tumorsneuroblastoma

Identifiers

PMID37480158
PMCPMC10527977
OpenAlexW4385063875

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.